Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts:
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Va. , March 5, 2015   HX360 ... as semi-finalists in the HX360 Innovation Challenge ... entries, will compete to be chosen as one of ... panel of senior health system executives and venture capitalists ... HX360 Innovation Challenge takes place at the 2015 HIMSS ...
(Date:3/5/2015)... York (PRWEB) March 05, 2015 LifeCell ... to be able to get an Advanced Semen Analysis ... stress, blaming and guessing are all risk factors for ... the woman is the source of the infertility. Infertility ... LifeCell Dx has the simplest, least complicated and ...
(Date:3/5/2015)... 2015 Plant disease specialists from around ... the Annual Meeting of The American Phytopathological Society. ... online now at APSnet.org/meet . , The Preliminary ... to be held August 1-5, 2015 in Pasadena, California, ... Trips, Workshops, and committee meetings, all carefully balanced to ...
(Date:3/5/2015)... Springs, FL (PRWEB) March 05, 2015 ... Damm for the position of Vice President of Managed ... managed care relationships for one of the nation’s leading ... brings more than 15 years of specialty pharmacy and ... Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. ...
Breaking Biology Technology:HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3American Phytopathological Society Announces Annual Meeting Daily Schedule 2BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... NS, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. ... an agreement with UK-based Scancell Ltd., the operating ... developing therapeutic cancer and infectious disease vaccines. This ... IVT,s DepoVax(TM) delivery system for Scancell,s novel ImmunoBody(R) ...
... - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... oncology, will announce its second quarter 2009 financial and operating ... Company will host a conference call and webcast to discuss ... Time. , Participants may access the live webcast via the ...
... , NEW HAVEN, Conn., Aug. 5 Rib-X ... on the discovery, development and commercialization of novel antibiotics for ... a Phase 2 clinical trial of radezolid in the treatment ... In the double-blind study, radezolid was administered orally at three ...
Cached Biology Technology:ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery 2Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 2Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 3Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 4
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2015)... 24, 2015 Research and Markets ... the "Global 2D Gesture Recognition Market 2015-2019" ... The analysts forecast the Global 2D Gesture Recognition ... over the period 2014-2019 The increased ... is one of the major trends in the ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... a person,s body mass consisting of skeletal muscle, chronic ... in the limbs can result in significant physical ... community health professor Kimberly Huey, past research has demonstrated ... associated with reduced expression of certain pro-inflammatory cytokines, in ...
... tool to monitor deforestation and degradation in tropical ... Gordon and Betty Moore Foundation has awarded the ... $1.6-million grant to expand and improve CLASLite (The ... method that enables even the smallest governments and ...
... site today, it,s easy to forget that a dam and ... Franbrook Farm Research Station in southwestern Wisconsin. All traces of ... and weedy, now carpet the floor of the former basin. ... into the soils of the basin, UW-Madison researchers are now ...
Cached Biology News:Vitamin E shows possible promise in easing chronic inflammation 2Vitamin E shows possible promise in easing chronic inflammation 3Tropical forest carbon monitoring gets big boost 2Researchers examine role of soil patterns in dam restoration 2Researchers examine role of soil patterns in dam restoration 3
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: